Full title
Authors
Lajos Zsom, S. Singh, S. McManus, M. Johnson, Kenneth Abreo
Summary
The publication examines the use of two-hour cyclosporine level monitoring in the long-term care of African American kidney transplant recipients. Cyclosporine is an important immunosuppressive drug after transplantation, helping to prevent rejection, but it requires careful dose adjustment because of its narrow therapeutic range. If drug exposure is too low, the risk of rejection may increase, while excessive exposure may lead to nephrotoxicity and other adverse effects.
The article focuses on C2 monitoring, which measures cyclosporine concentration two hours after drug administration. This approach may provide a more accurate estimate of absorption and systemic exposure than traditional trough-level monitoring. The authors evaluated whether C2-based monitoring was effective, safe and feasible in stable renal transplant patients in the maintenance phase of treatment.
The practical significance of the publication lies in highlighting the role of cyclosporine monitoring after kidney transplantation. More precise drug-level follow-up may support individualized immunosuppressive therapy, help protect graft function and reduce the risk of drug-related toxicity. This may be especially important in patient groups where drug metabolism, absorption or clinical response can vary, making patient-specific monitoring a key part of long-term transplant care.
